Panel: R&D in a Capital-Disciplined Market: Portfolio Triage and Build-Partner-Buy Decisions

Session details:

Drug development leaders are redesigning portfolios and operating models under tighter capital and higher proof requirements. This session focuses on how teams are prioritizing programs, de-risking earlier, and deciding when to build internally versus partner or acquire. 

Key discussion points: 
• Which programs get cut and why: evidence thresholds for continuation 
• Platform consolidation vs indication expansion strategies 
• Licensing and partnership structures that preserve optionality 
• How CEOs and R&D heads align science with financial runway and milestones